Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445169 · ClinicalTrials.gov registry record · Phase 1
A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets
A Phase 1 study, sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03445169 is a Phase 1 study that has completed, run by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 16 participants.
The verdict
NCT03445169, a Phase 1 study, has completed, sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of belzutifan Tablets. The study will consist of two periods and will be conducted in a crossover fashion.
Interventions
- DRUG Belzutifan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2018-05-26 |
| Phase | Phase 1 |
Sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03445169
The ClinicalTrials.gov registry entry for NCT03445169 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belzutifan is the first listed.
NCT03445169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03445169 about?
NCT03445169 is a clinical study titled "A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets". This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of belzutifan Tablets. The st...
What is the current status of trial NCT03445169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-02-23. Estimated completion is 2018-05-26.
What interventions are being tested in trial NCT03445169?
The interventions under investigation include: Belzutifan (DRUG).
Who is sponsoring clinical trial NCT03445169?
This trial is sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.